Charlie Strange to Scleroderma, Systemic
This is a "connection" page, showing publications Charlie Strange has written about Scleroderma, Systemic.
Connection Strength
0.501
-
Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med. 2008 Jan 01; 177(1):91-8.
Score: 0.220
-
Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension. Chest. 2000 Oct; 118(4):1077-82.
Score: 0.135
-
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016 09; 4(9):708-719.
Score: 0.101
-
Interstitial lung disease in the patient who has connective tissue disease. Clin Chest Med. 2004 Sep; 25(3):549-59, vii.
Score: 0.044